PIKASO Trial Investigates Metformin for Preventing Post-ACL Surgery Osteoarthritis
The Arthritis Foundation launches its first directed clinical trial PIKASO, investigating Metformin's potential to prevent post-traumatic osteoarthritis in patients undergoing ACL reconstruction.
Cholecalciferol and Silymarin Combination Shows Promise in Alleviating BPH-Related LUTS
A study reveals that combined cholecalciferol and silymarin significantly improve lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH) patients with vitamin D deficiency.
Librexia Program Aims for Inclusive Cardiovascular Clinical Trials
The Librexia program is a Phase 3 clinical trial focusing on novel treatments for blood clotting diseases, including acute coronary syndrome and atrial fibrillation.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Induction Regimen in Ulcerative Colitis
Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya.
Low-Level Laser Therapy Shows Promise in Accelerating Orthodontic Tooth Movement
A recent umbrella review indicates that photobiomodulation with low-level lasers can effectively accelerate orthodontic tooth movement.
CBD Shows Promise in Treating Neuropsychiatric Disorders in Tuberous Sclerosis Complex
Phase 4 EpiCom study reveals cannabidiol (CBD) has positive effects on psychiatric and behavioral problems in patients with tuberous sclerosis complex (TSC).
Biohaven Launches Phase 2 Trial of TRPM3 Antagonist BHV-2100 for Acute Migraine Treatment
Biohaven has initiated a Phase 2 clinical trial to evaluate BHV-2100, a novel, orally administered TRPM3 antagonist, for the acute treatment of migraine.
Postbiotic Supplementation Shows Promise in Reducing Inflammation and Pneumonia Risk in Stroke Patients
A randomized controlled trial reveals that postbiotic supplementation significantly reduces inflammation and oxidative stress in patients with cerebrovascular accident (CVA).
Biofrontera Announces Database Lock for Phase 3 sBCC Study of Ameluz®-PDT
Biofrontera has locked the database for its Phase 3 trial evaluating Ameluz®-PDT for superficial basal cell carcinoma (sBCC) treatment.
Formycon's FYB206 Shows High Similarity to Keytruda in Analytical Study
Formycon's biosimilar candidate FYB206 demonstrates high structural and functional similarity to Keytruda in a comparative analytical evaluation, according to a publication in _Drugs in R&D_.
EMA Rejects Renewal of Translarna for Duchenne Muscular Dystrophy After Re-Examination
The European Medicines Agency (EMA) has upheld its decision against renewing the marketing authorization for Translarna (ataluren) for Duchenne muscular dystrophy.
CGM and Machine Learning Identify Metabolic Subphenotypes in Type 2 Diabetes
A recent study leverages continuous glucose monitoring (CGM) and machine learning to identify distinct metabolic subphenotypes within type 2 diabetes.
Ventus Therapeutics' VENT-03 Demonstrates Promising Phase 1 Results as First-in-Class cGAS Inhibitor
Ventus Therapeutics announced positive Phase 1 clinical trial results for VENT-03, a first-in-class oral cGAS inhibitor, showing it was safe and well-tolerated in healthy volunteers.
Mark Prausnitz Elected to National Academy of Medicine for Microneedle Technology Innovations
Mark Prausnitz was elected to the National Academy of Medicine for his pioneering work in microneedle technology for drug and vaccine delivery.
Sagimet's Denifanstat Advances to Phase 3 for MASH Following FDA Interactions
Sagimet Biosciences has completed end-of-Phase 2 interactions with the FDA, clearing the path for Phase 3 trials of denifanstat in MASH.
Journey Medical's Emrosi Receives FDA Approval for Rosacea Treatment
The FDA has approved Journey Medical's Emrosi (minocycline hydrochloride extended-release capsules, 40 mg) for treating inflammatory lesions of rosacea in adults.
Baekhogainsam-Tang and Low-Dose Pilocarpine Combination Shows Promise for Xerostomia
A randomized controlled trial is underway to evaluate the efficacy and safety of combining Baekhogainsam-Tang (BIT) with low-dose pilocarpine for intractable xerostomia.
Hanmi Pharmaceutical Fast-Tracks Efeglenatide Launch for Obesity Treatment
Hanmi Pharmaceutical is accelerating the launch of Efeglenatide, an obesity drug, to the second half of 2026, ahead of its initially planned 2027 release.
FDA Approves Alvotech and Teva's SELARSDI (ustekinumab-aekn) for Crohn's Disease and Ulcerative Colitis
The FDA has approved a new intravenous infusion presentation of SELARSDI, expanding its label to include Crohn’s disease and ulcerative colitis.
Setmelanotide Shows Promise in Reducing Obesity in Young Children With Rare Genetic Deficiencies
A Phase 3 trial of setmelanotide in children aged 2-5 years with Bardet-Biedl syndrome or POMC, PCSK1, or LEPR deficiency demonstrated clinically meaningful reductions in BMI Z-score.